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Abstract
© 2015 © 2015 Taylor & Francis. ARID1A is a subunit of the Switch/Sucrose Non-Fermentable
(SWI/SNF) chromatin-remodeling complex that regulates gene expression by controlling gene
accessibility. ARID1A shows one of the highest mutation rates across different human cancer
types. For example, ARID1A is mutated in ∼ 50% of ovarian clear cell carcinoma (OCCC). There
is considerable interest in developing cancer therapeutics that correlate with ARID1A mutational
status.  A  recent  study  demonstrated  a  synthetic  lethality  by  targeting  EZH2  histone
methyltransferase activity in ARID1A-mutated OCCC using a clinically applicable small-molecule
inhibitor. The observed synthetic lethality correlated with inhibition of PI3K/AKT signaling. In
addition, there is evidence indicating that ARID1A-mutated cancer may also be subjected to
therapeutic intervention by targeting residual SWI/SNF activity, the PI3K/AKT pathway, the DNA
damage response, the tumor immunological microenvironment and stabilizing wild-type p53. In
summary,  we propose  EZH2 inhibitor-based combinatorial  strategies  for  targeting  ARID1A-
mutated cancers.
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